Skip to: Content
Skip to: Site Navigation
Skip to: Search
SATURDAY, JULY 4, 2009

« Back to the grid | Next story »

Many Cancer Trials Go Unpublished: Study

(Newser Summary) – Fewer than 20% of cancer trial results are published in peer-review journals, a new study says. And industry-sponsored trials only achieve publication one time in 20. The reason? Scientists seeking success and media-hungry journals don't want to publish negative results, analysts say—even if they would aid other cancer studies.

"I knew that there was underpublication," but not at such high rates, study author Dr. Scott Ramsey told BusinessWeek. "We were really shocked by that." Studies that negated a drug's effects may have gone unpublished, he said, while positive ones were. Then "not only are we wasting lots of money, but we'd be giving patients false hopes about the value of the products."
Source: BusinessWeek

elsewhere: Findings could renew focus on FDA policy newsinferno.com • PDF of the original study The Oncologist • New website hopes to close the gap Los Angeles Times

More about:  FDA • pharmaceutical companies • clinical trials • cancer prevention • journals

Many science journals refuse to publish negative results....
Many science journals refuse to publish negative results. "There are some journals which say, 'If you have negative results, we don't want to publish them,'" said one researcher. "It's dysfunctional."   (Index Stock)
The findings are particularly worrisome for cancer...
The findings are particularly worrisome for cancer patients, given that many expensive new drugs have only modest survival benefits, adding at best a few months of life.   (Shutter Stock)
Experts say there are powerful incentives for researchers...
Experts say there are powerful incentives for researchers not to publish negative results, especially because scientists gain career advancement, money, and fame by making bold advances.   (Index Stock)
This clinical trial blackout is a huge problem in...
This clinical trial blackout is a huge problem in cancer research, BusinessWeek reports.   (Shutter Stock)
« Prev« Prev | Next »Next » Slideshow
0 comments
VIEWING:
 
LEAVE A
COMMENT Comment Policy

 

Related Newser Stories

18 Stories

Anti-Smoking Chantix, Zyban Pose Suicide Risk: FDA

Smokers with mental illnesses should avoid them, agency says

New York Times New York Times Jul 1, 09 4:59 PM CDT
(Newser Summary) - The Food and Drug Administration is warning smokers about serious mental-illness risks of two smoking-cessation drugs, as reported suicides among their users increase. Chantix and Zyban must now carry the agency’s strongest warning label, the New York Times reports. The FDA isn’t trying to scare patients, an official says: “You should just be careful.” More »

More about:  FDA • pharmaceutical companies • Pfizer • GlaxoSmithKline • smoking cessation • Chantix

FDA: Get Off Smell-Killing Zicam Nasal Spray, Now

Agency received over 130 reports of loss of smell sense

Wall Street Journal Wall Street Journal Jun 16, 09 12:47 PM CDT
(Newser Summary) - The Food and Drug Administration is calling on consumers to stop using Zicam nasal treatments because they can permanently kill the sense of smell, the Wall Street Journal reports. Zicam is an over-the-counter cold and allergy medication sold in several forms; customers should reject internasal products that contain zinc. The initiative comes after the agency received more than 130 reports of loss of smell. More »

More about:  FDA • medicine • pharmaceutical companies • drug companies • medication • smell • drug safety • cold • allergy • sense of smell • warning • nasal passages

FDA OKs Pioneering
Stem Cell Trial

First-ever test of therapy on spinal cord injuries hailed as milestone

New York Times New York Times Jan 23, 09 3:00 AM CST
(Newser Summary) - The FDA has approved the world's first-ever human trial of a medical treatment using embryonic stem cells, the New York Times reports. The move is being hailed as a watershed moment for medical research. Biotech company Geron plans to inject the cells—which can turn into any type of cell in the body—into people with new, severe spinal cord injuries in an attempt to repair some of the damage. More »

More about:  FDA • stem cell research • stem cells • clinical trials • biotechnology • spinal cord

Drug Companies Hide Data
From Docs

Edited info could mislead those prescribing meds

Wired Wired Nov 26, 08 10:22 AM CST
(Newser Summary) - Pharmaceutical companies aren't as upfront with doctors as they are with the government about their new products, a study finds. Though drug companies must provide the FDA with all of the data from clinical trials, related papers published in medical journals were found to omit info from 20% of the trials, and were often presented with a favorable twist, Wired reports . More »

More about:  FDA • prescription drugs • pharmaceutical companies • doctors • side effects • Avandia • prescription • Vioxx • Vytorin • Merck and Co.

Opinion

How Congress Can Help
Ted Kennedy

New bill would give terminally ill access to unproven drugs

Wall Street Journal Wall Street Journal Jun 11, 08 8:00 AM CDT
(Newser Summary) - Ted Kennedy has, at best, about two years to live. A drug exists that might extend his life, but Kennedy, and legions of other cancer sufferers, won’t get it because it hasn’t been through Phase III FDA trials. But congress could yet come to the rescue; a bill recently introduced in the Senate would give the terminally ill access to unproven treatments. More »

More about:  drugs • FDA • Ted Kennedy • brain cancer • clinical trials • pharmaceutical • experimental drugs

18 Stories

Today's Most Popular

Loading...

PREMIUM NEWS ARCHIVE

Cancer in Children Awareness Month.(Opinion) (Manila Bulletin)

New findings from T. Wolff and co-researchers in the area of skin cancer described. (Cancer Weekly)

Cancer incidence and mortality drops among American men and women, according... (NewsRx Health & Science)

Recent findings in breast cancer described by K. Pant and colleagues. (Cancer Weekly)

ASGE and the Pancreatic Cancer Action Network Partner to Raise Awareness About... (Cancer Weekly)

Studies from National Cancer Center add new findings in the area of lung cancer... (Cancer Weekly)

Breast cancer: educating the educator.(Clinical Research Corner)(Brief article) (Nevada RNformation)

Lung Cancer in Non-Smokers Is Sixth Biggest Cancer Killer. (Blood Weekly)

In the pink; Breast Cancer Awareness With October comes Breast Cancer Awareness... (The Journal (Newcastle, England))

Breast Cancer; Overview. (NWHRC Health Center - Breast Cancer)